Multiple combinatory approaches of third-generation EGFR TKIs with additional therapies—such as osimertinib plus platinum-based chemotherapy (FLAURA2 trial, NCT04035486) [10] or lazertinib plus amivantamab (MARIPOSA trial, NCT04487080) [11]—have been recently reported and may lead to newer approaches for the first-line management of EGFRm NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.